Amazon has a lot of tailwinds blowing in its favor.Amazon (AMZN -0.01%) has been a great performer this year, as it's up more than 20%. However, I believe this is just the start of a much larger move.Amazon's business is starting to transform into something investors have never seen, and that's fantastic news. I've got three facts about Amazon that investors should know. While there are many more reasons to be interested in Amazon stock, I think these combine to make a compelling case to buy right now.1. Am ...

Group 1: Walmart - Walmart reported consolidated revenue of $161.5 billion for Q1 fiscal 2025, a 6% increase year over year [2] - The company's e-commerce business grew globally by 21%, while its advertising business achieved a growth rate of 24% [2] - Walmart plans to expand or open 150 stores in the U.S. over the next five years [2] - The company has a history of annual dividend increases for 51 consecutive years, with a yield of 1.3% [3] Group 2: Apple - Apple generated $100.4 billion in profit and $101.9 billion in free cash flow over the trailing 12 months [4] - The company announced a record $110 billion stock repurchase plan, which positively impacted its stock price [4] - In the most recent quarter, Apple reported net sales of $90.8 billion, a 4% decline year over year, but achieved an all-time record for services revenue at $23.9 billion [5] - Apple is rumored to be developing a chatbot to rival ChatGPT and is incorporating AI capabilities into its latest phones [5] Group 3: Eli Lilly - Eli Lilly has a market cap of $730 billion and pays a modest dividend with a yield of 0.7% [6] - The company has diverse products across multiple therapeutic areas, with a strong focus on diabetes and obesity control [6] - The new diabetes drug Mounjaro generated $1.8 billion in revenue in Q1, surpassing the flagship product Trulicity [7] - Recently approved Zepbound, similar to Mounjaro but for weight loss, generated $517 million in revenue [7] - Eli Lilly's potential Alzheimer's treatment, donanemab, could further enhance growth if approved [7] - The company has high profit margins exceeding 17% and a valuation of over 110 times trailing earnings, indicating strong growth potential [7]

It's clear these hedge funds are sticking to established players.Keeping tabs on what billionaire hedge fund managers do is a great way to check your investment strategy. While blindly following them isn't advisable, seeing what they're doing and checking that against your own thoughts is a good way of seeing if you're on the same page, especially when there's a hot trend like artificial intelligence (AI).The 13F filings for Q1 were recently released, revealing some common themes across hedge funds. While m ...

This top pharma stock has fallen too far.Dividend stocks are an important anchor for well-balanced portfolios. Regular cash distributions can buffer a portfolio against market volatility and provide a steady income across business cycles.Still, picking dividend stocks is no easy task. Companies operating in high-tech areas like healthcare often face unique competitive pressures that can diminish free cash flows, lowering their ability to reward shareholders via ever-larger dividend checks. Bristol Myers Squ ...

Core Insights - Eli Lilly has made significant clinical and regulatory advancements, leading to strong stock performance and investor interest [1] - The company is developing a once-weekly insulin product, efsitora alfa, which has shown positive phase 3 results against daily insulin for type 2 diabetes patients [2] - Despite competition from Novo Nordisk, efsitora alfa has the potential to contribute significantly to Eli Lilly's revenue due to the large addressable market of diabetes patients [4] Company Developments - Eli Lilly's efsitora alfa demonstrated non-inferiority to daily insulin and a safety profile consistent with it, making it a promising option for eligible patients [2] - The company reported a 26% year-over-year revenue increase to $8.8 billion in the first quarter [4] - Key growth drivers include Zepbound for diabetes and Mounjaro for obesity, both of which are expected to sustain sales growth for years [5][6] Market Position - Eli Lilly is a leader in the insulin market, competing with Novo Nordisk and Sanofi, and must continue to innovate to maintain its position [2][3] - The prevalence of diabetes is projected to increase, expanding the market for efsitora alfa, which targets the 90% of diabetes patients with type 2 diabetes [4] - Analysts predict Eli Lilly's earnings per share will grow at an average of just under 57% over the next five years, indicating strong bottom-line growth [6]

These companies' investments in artificial intelligence (AI) could help them -- and investors -- win big.The Nasdaq roared to a record high earlier this year, confirming the presence of a bull market. But it didn't stop there. The index continues to climb, just recently reaching yet another new high as investors pile into technology stocks and other growth players. This is great, but if you're looking to buy tech stocks, you might be wondering if valuations have become too lofty.I've got good news for you: ...

It might not be too late to invest in these impressive growth stocks.The Great Recession ended nearly 15 years ago. Buying stocks toward the end of an economic slowdown can lead to some oversize returns down the road since that usually means you're buying them at reduced prices, when optimism in the markets could still be a bit muted.If you invested $25,000 at the end of the Great Recession in any of the stocks on this list, your investment would now be worth more than $1 million. Nvidia (NVDA -0.46%), Netf ...

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Applied Materials. The Motley Fool recommends Intel and recommends the following options: long January 2025 $45 calls on Intel and short May 2024 $47 calls on Intel. The Motley Fool has a disclosure policy.Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that sup ...

Alphabet's bread and butter is search and advertising, but there's so much more to its business.Out of all the "Magnificent Seven," Google parent Alphabet (GOOG -0.86%) (GOOGL -0.83%) seems to be the one that is constantly undervalued. In this video, I will explain why that is.*Stock prices used were from the trading day of May 21, 2024. The video was published on May 22, 2024. ...

Did Nvidia meet investors' expectations?In today's video, I discuss recent updates impacting Nvidia (NVDA -0.46%). Check out the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were the after-market prices of May 22, 2024. The video was published on May 22, 2024. ...